MD20160003A2 - Sare nouă de 3-[(3-{[4-(4-morfolinilmetil)-1H-pirol-2-il]metilen}-2-oxo-2,3-dihidro-1H-indol-5-il)metil]-1,3-tiazolidină-2,4-dionă, procedeu de obţinere a ei şi forme preparative care o conţin - Google Patents

Sare nouă de 3-[(3-{[4-(4-morfolinilmetil)-1H-pirol-2-il]metilen}-2-oxo-2,3-dihidro-1H-indol-5-il)metil]-1,3-tiazolidină-2,4-dionă, procedeu de obţinere a ei şi forme preparative care o conţin Download PDF

Info

Publication number
MD20160003A2
MD20160003A2 MDA20160003A MD20160003A MD20160003A2 MD 20160003 A2 MD20160003 A2 MD 20160003A2 MD A20160003 A MDA20160003 A MD A20160003A MD 20160003 A MD20160003 A MD 20160003A MD 20160003 A2 MD20160003 A2 MD 20160003A2
Authority
MD
Moldova
Prior art keywords
morpholinylmethyl
thiazolidine
pyrrol
indol
dihydro
Prior art date
Application number
MDA20160003A
Other languages
English (en)
Russian (ru)
Other versions
MD4507C1 (ro
MD4507B1 (ro
Inventor
Flohic Alexandre Le
Jérôme Guidotti
Philippe Letellier
Original Assignee
Les Laboratoires Servier
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Les Laboratoires Servier filed Critical Les Laboratoires Servier
Publication of MD20160003A2 publication Critical patent/MD20160003A2/ro
Publication of MD4507B1 publication Critical patent/MD4507B1/ro
Publication of MD4507C1 publication Critical patent/MD4507C1/ro

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/53751,4-Oxazines, e.g. morpholine
    • A61K31/53771,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425Thiazoles
    • A61K31/427Thiazoles not condensed and containing further heterocyclic rings
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D417/00Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/14Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07BGENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00Indexing scheme relating to specific properties of organic compounds
    • C07B2200/13Crystalline forms, e.g. polymorphs

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

Invenţia se referă la o sare nouă de metansulfonat de 3-[(3-{[4-(4-morfolinilmetil)-1H-pirol-2-il]metilen}-2-oxo-2,3-dihidro-1H-indol-5-il)metil]-1,3-tiazolidină-2,4-dionă cu formula (II):,care posedă proprietăţi farmacologice în domeniul oncologiei.Invenţia se referă, de asemenea, la un procedeu de obţinere a ei şi la compoziţii farmaceutice care o conţin.
MDA20160003A 2013-07-12 2014-07-11 Metansulfonat de 3-[((3Z)-3-{[4-(4-morfolinilmetil)-1H-pirol-2-il]metilen}-2-oxo-2,3-dihidro-1H-indol-5-il)metil]-1,3-tiazolidin-2,4-dionă, procedeu de obţinere a lui şi forme preparative care îl conţin MD4507C1 (ro)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
FR1356870A FR3008411B1 (fr) 2013-07-12 2013-07-12 Nouveau sel de la 3-[(3-{[4-(4-morpholinylmethyl)-1h-pyrrol-2-yl]methylene}-2-oxo-2,3-dihydro-1h-indol-5-yl)methyl]-1,3-thiazolidine-2,4-dione, sa preparation, et les formulations qui le contiennent
PCT/FR2014/051783 WO2015004395A1 (fr) 2013-07-12 2014-07-11 Nouveau sel de la 3-[(3-{[4-(4-morpholinylméthyl)-1h-pyrrol-2-yl]méthylène}-2-oxo-2,3-dihydro-1h-indol-5-yl)méthyl]-1,3-thiazolidine-2,4-dione, sa préparation, et les formulations qui le contiennent

Publications (3)

Publication Number Publication Date
MD20160003A2 true MD20160003A2 (ro) 2016-06-30
MD4507B1 MD4507B1 (ro) 2017-08-31
MD4507C1 MD4507C1 (ro) 2018-03-31

Family

ID=50424327

Family Applications (1)

Application Number Title Priority Date Filing Date
MDA20160003A MD4507C1 (ro) 2013-07-12 2014-07-11 Metansulfonat de 3-[((3Z)-3-{[4-(4-morfolinilmetil)-1H-pirol-2-il]metilen}-2-oxo-2,3-dihidro-1H-indol-5-il)metil]-1,3-tiazolidin-2,4-dionă, procedeu de obţinere a lui şi forme preparative care îl conţin

Country Status (47)

Country Link
US (2) US9925195B2 (ro)
EP (1) EP3019497B1 (ro)
JP (1) JP6532459B2 (ro)
KR (2) KR20180028554A (ro)
CN (1) CN105377843B (ro)
AP (1) AP2016008976A0 (ro)
AR (1) AR096882A1 (ro)
AU (1) AU2014289059B2 (ro)
CA (1) CA2916380C (ro)
CL (1) CL2016000013A1 (ro)
CR (1) CR20160012A (ro)
CU (1) CU20160005A7 (ro)
CY (1) CY1119259T1 (ro)
DK (1) DK3019497T3 (ro)
DO (1) DOP2016000005A (ro)
EA (1) EA031526B1 (ro)
ES (1) ES2632570T3 (ro)
FR (1) FR3008411B1 (ro)
GE (1) GEP201706712B (ro)
GT (1) GT201600004A (ro)
HK (1) HK1222172A1 (ro)
HR (1) HRP20171060T1 (ro)
HU (1) HUE032568T2 (ro)
IL (1) IL243526B (ro)
JO (1) JO3292B1 (ro)
LT (1) LT3019497T (ro)
MA (1) MA38759B1 (ro)
MD (1) MD4507C1 (ro)
ME (1) ME02735B (ro)
MX (1) MX360291B (ro)
MY (1) MY183197A (ro)
NI (1) NI201600009A (ro)
NZ (1) NZ715841A (ro)
PE (1) PE20160079A1 (ro)
PH (1) PH12016500017B1 (ro)
PL (1) PL3019497T3 (ro)
PT (1) PT3019497T (ro)
RS (1) RS55945B1 (ro)
RU (1) RU2680826C9 (ro)
SA (1) SA516370388B1 (ro)
SG (1) SG11201510570YA (ro)
SI (1) SI3019497T1 (ro)
TN (1) TN2015000566A1 (ro)
TW (2) TWI554510B (ro)
UA (1) UA114041C2 (ro)
UY (1) UY35629A (ro)
WO (1) WO2015004395A1 (ro)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US10245270B2 (en) * 2013-07-12 2019-04-02 Les Laboratoires Servier Salt of 3-[(3-{[4-(4-morpholinylmethyl)-1H-pyrrol-2-yl]methylene}-2-oxo-2,3-dihydro-1H-indol-5-yl)methyl]-1,3-thiazolidine-2,4-dione, its preparation, and formulations containing it
FR3039401B1 (fr) * 2015-07-31 2018-07-13 Les Laboratoires Servier Nouvelle association entre le 3-[(3-{[4-(4-morpholinylmethyl)-1h-pyrrol-2-yl]methylene}-2-oxo-2,3-dihydro-1h-indol-5-yl)methyl]-1,3-thiazolidine-2,4-dione et un inhibiteur de la tyr kinase du egfr

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SI1255752T1 (sl) * 2000-02-15 2007-12-31 Pharmacia & Upjohn Co Llc S pirolom substituirani zaviralci 2-indolinon protein kinaza
AU2002226877B2 (en) * 2000-10-17 2006-01-12 Merck & Co., Inc. Orally active salts with tyrosine kinase activity
AR042586A1 (es) * 2001-02-15 2005-06-29 Sugen Inc 3-(4-amidopirrol-2-ilmetiliden)-2-indolinona como inhibidores de la protein quinasa; sus composiciones farmaceuticas; un metodo para la modulacion de la actividad catalitica de la proteinquinasa; un metodo para tratar o prevenir una afeccion relacionada con la proteinquinasa
ATE302771T1 (de) * 2001-12-27 2005-09-15 Theravance Inc Indolinon-derivative als protein-kinasehemmer
JP2007509173A (ja) * 2003-10-24 2007-04-12 シエーリング アクチエンゲゼルシャフト インドリノン誘導体類及び疾病状態、例えば癌の処理へのそれらの使用
TWI403493B (zh) * 2005-12-05 2013-08-01 Xenoport Inc 左旋多巴前藥的甲磺酸鹽,其組成物,及其用途
FR2948940B1 (fr) * 2009-08-04 2011-07-22 Servier Lab Nouveaux derives dihydroindolones, leur procede de preparation et les compositions pharmaceutiques qui les contiennent

Also Published As

Publication number Publication date
UY35629A (es) 2015-01-30
AU2014289059B2 (en) 2017-05-25
HK1222655A1 (zh) 2017-07-07
ES2632570T3 (es) 2017-09-14
TW201630906A (zh) 2016-09-01
MA38759A1 (fr) 2018-01-31
TWI554510B (zh) 2016-10-21
MD4507C1 (ro) 2018-03-31
CA2916380C (fr) 2017-11-21
SG11201510570YA (en) 2016-01-28
WO2015004395A1 (fr) 2015-01-15
TN2015000566A1 (fr) 2017-04-06
EA201600101A1 (ru) 2016-06-30
MA38759B1 (fr) 2018-09-28
CY1119259T1 (el) 2018-02-14
GT201600004A (es) 2018-09-28
TW201504236A (zh) 2015-02-01
KR20160030399A (ko) 2016-03-17
AP2016008976A0 (en) 2016-01-31
MX2016000332A (es) 2016-05-09
US20160151378A1 (en) 2016-06-02
GEP201706712B (en) 2017-07-25
MY183197A (en) 2021-02-18
DK3019497T3 (en) 2017-08-07
FR3008411B1 (fr) 2015-07-03
CA2916380A1 (fr) 2015-01-15
CU20160005A7 (es) 2016-05-30
JO3292B1 (ar) 2018-09-16
RU2680826C2 (ru) 2019-02-28
US9925195B2 (en) 2018-03-27
JP2016523953A (ja) 2016-08-12
HRP20171060T1 (hr) 2017-10-06
AR096882A1 (es) 2016-02-03
PL3019497T3 (pl) 2017-09-29
CN105377843A (zh) 2016-03-02
HK1222172A1 (zh) 2017-06-23
CL2016000013A1 (es) 2016-08-12
IL243526A0 (en) 2016-02-29
EP3019497B1 (fr) 2017-04-12
SI3019497T1 (sl) 2017-07-31
DOP2016000005A (es) 2016-12-15
PH12016500017B1 (en) 2019-06-26
CR20160012A (es) 2016-02-08
EA031526B1 (ru) 2019-01-31
PE20160079A1 (es) 2016-02-06
UA114041C2 (xx) 2017-04-10
IL243526B (en) 2019-09-26
LT3019497T (lt) 2017-05-25
KR20180028554A (ko) 2018-03-16
EP3019497A1 (fr) 2016-05-18
NZ715841A (en) 2019-04-26
PH12016500017A1 (en) 2016-04-18
PT3019497T (pt) 2017-05-15
NI201600009A (es) 2016-02-11
HUE032568T2 (hu) 2017-09-28
AU2014289059A1 (en) 2016-02-04
US20180207171A1 (en) 2018-07-26
MX360291B (es) 2018-10-29
RS55945B1 (sr) 2017-09-29
SA516370388B1 (ar) 2017-12-14
CN105377843B (zh) 2019-03-05
RU2016104642A (ru) 2017-08-17
JP6532459B2 (ja) 2019-06-19
ME02735B (me) 2017-10-20
FR3008411A1 (fr) 2015-01-16
RU2680826C9 (ru) 2019-03-01
MD4507B1 (ro) 2017-08-31

Similar Documents

Publication Publication Date Title
MY176307A (en) Aryl and heteroaryl fused lactams
PH12015501996A1 (en) Heterocyclic compounds and uses thereof
UA117122C2 (uk) Хінолонові похідні
PH12014000179A1 (en) New pyrrole compounds, a process for their preparation and pharmaceutical compositions containing them
PH12014502540B1 (en) Benzimidazole-proline derivatives
UA117020C2 (uk) Нові сполуки індолу і піролу, спосіб їх одержання і фармацевтичні композиції, що їх містять
TN2016000003A1 (en) New isoindoline or isoquinoline compounds, a process for their preparation and pharmaceutical compositions containing them
MY176244A (en) Crystalline salt form of (s)-(2-(6-chloro-7-methyl-1h-benzo[d]imidazol-2-yl)-2-methylpyrrolidin-1-yl)(5-methoxy-2-(2h-1,2,3-triazol-2-yl)phenyl)methanone as orexin receptor antagonist
MX2015007126A (es) Piridopirazinas sustituidas como inhibidores de syk.
PH12016500988B1 (en) Crystalline form of (s)-(2-(6-chloro-7-methyl-1h-benzo[d]imidazol-2-yl)-2-methylpyrrolidin-1 -yl)(5-methoxy-2-(2h-1,2,3-triazol-2-yl)phenyl)methanone and its use as orexin receptor antagonists
MD20160003A2 (ro) Sare nouă de 3-[(3-{[4-(4-morfolinilmetil)-1H-pirol-2-il]metilen}-2-oxo-2,3-dihidro-1H-indol-5-il)metil]-1,3-tiazolidină-2,4-dionă, procedeu de obţinere a ei şi forme preparative care o conţin

Legal Events

Date Code Title Description
FG4A Patent for invention issued
KA4A Patent for invention lapsed due to non-payment of fees (with right of restoration)
MM4A Patent for invention definitely lapsed due to non-payment of fees